{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T18:06:56Z","timestamp":1783793216434,"version":"3.55.0"},"reference-count":29,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Peptide receptor activation therapy (PRRT) is a promising treatment option for metastatic neuroendocrine tumors (NETs). However, predicting tumor shrinkage before treatment is challenging. We analyzed the shrinkage rate of each metastatic tumor lesion to identify predictive factors related to shrinkage. Patients with metastatic NET who underwent PRRT were included in this retrospective study. For each patient, between one to five metastatic lesions were selected in descending order of size, and the change in the maximum tumor diameter after treatment was defined as the shrinkage rate per lesion (L-SR). We analyzed the relationship between pretreatment clinicopathological factors and L-SR. The median L-SR of all 75 lesions in 20 patients was 20% (95% CI: 4.8\u201326.1%). While previous treatment with cytotoxic agents (34.4%, p &lt; 0.05) and primary tumor of the pancreas (27.8%, p &lt; 0.05) were significantly favorable factors, a primary tumor of the rectum was significantly more resistant to shrinkage (\u221220.5%, p &lt; 0.001). Therefore, lesion-based analysis of PRRT for NETs showed that pancreatic NET and previous treatment with cytotoxic agents were favorable factors for tumor shrinkage; however, rectal NET was a factor associated with resistance to shrinkage.<\/jats:p>","DOI":"10.3390\/cancers14143317","type":"journal-article","created":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T22:11:47Z","timestamp":1657231907000},"page":"3317","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors"],"prefix":"10.3390","volume":"14","author":[{"given":"Sho","family":"Hasegawa","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology Division, Yokohama City University Hospital, Yokohama 2360004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noritoshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Oncology Division, Yokohama City University Hospital, Yokohama 2360004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-5350","authenticated-orcid":false,"given":"Damian","family":"Wild","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0621-4072","authenticated-orcid":false,"given":"Fesupplix","family":"Kaul","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Division, University Hospital Basel, 4031 Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Okubo","sequence":"additional","affiliation":[{"name":"Oncology Division, Yokohama City University Hospital, Yokohama 2360004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Oncology Division, Yokohama City University Hospital, Yokohama 2360004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kurita","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Division, Yokohama City University Hospital, Yokohama 2360004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Takano","sequence":"additional","affiliation":[{"name":"Radiation Oncology Division, Yokohama City University Hospital, Yokohama 2360004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6263-1436","authenticated-orcid":false,"given":"Atsushi","family":"Nakajima","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Division, Yokohama City University Hospital, Yokohama 2360004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ichikawa","sequence":"additional","affiliation":[{"name":"Oncology Division, Yokohama City University Hospital, Yokohama 2360004, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/jhbp.225","article-title":"The up-to-date review of epidemiological pancreatic neuroendocrine tumors in Japan","volume":"22","author":"Ito","year":"2015","journal-title":"J. Hepato-Bil. Pancreat. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1053\/j.gastro.2008.05.047","article-title":"Gastrointestinal neuroendocrine tumors: Pancreatic endocrine tumors","volume":"135","author":"Metz","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000464292","article-title":"ENETS consensus guidelines for standard of care in neuroendocrine tumours: Surgery for small intestinal and pancreatic neuroendocrine tumours","volume":"105","author":"Partelli","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.4158\/EP151172.OR","article-title":"Evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): A randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr. Pract."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000117575","article-title":"Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors","volume":"88","author":"Fjallskog","year":"2008","journal-title":"Neuroendocrinology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1677\/ERC-09-0104","article-title":"Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710","volume":"16","author":"Dahan","year":"2009","journal-title":"Endocr. Relat. Cancer."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/sj.bjc.6605618","article-title":"Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours","volume":"102","author":"Turner","year":"2010","journal-title":"Br. J. Cancer."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11307-014-0795-3","article-title":"SUV of [68Ga] DOTATOC-PET\/CT predicts response probability of PRRT in neuroendocrine tumors","volume":"17","author":"Kratochwill","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1007\/s00259-020-04709-x","article-title":"Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: An analysis of the NETTER-1 study","volume":"47","author":"Strosberg","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16932","DOI":"10.18632\/oncotarget.24524","article-title":"Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms","volume":"9","author":"Baum","year":"2018","journal-title":"Oncotarget"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/ERC-19-0400","article-title":"PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)","volume":"27","author":"Sorbye","year":"2020","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/jhbp.1014","article-title":"Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors","volume":"28","author":"Kobayashi","year":"2021","journal-title":"J. Hepato-Bil. Pancreat. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_20","first-page":"652","article-title":"Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"J. Nucl. Med."},{"key":"ref_21","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90) Y-DOTATOC","volume":"43","author":"Waldherr","year":"2002","journal-title":"J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000324096","article-title":"Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: Results from a Danish cohort treated in Switzerland","volume":"93","author":"Pfeifer","year":"2011","journal-title":"Neuroendocrinology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s00259-013-2402-2","article-title":"Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: Factors associated with response and suggestions for therapeutic sequence","volume":"40","author":"Campana","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","article-title":"Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours","volume":"41","author":"Ezziddin","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1158\/1078-0432.CCR-16-2743","article-title":"Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors","volume":"23","author":"Brabander","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1007\/s00259-018-4196-8","article-title":"Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)","volume":"46","author":"Kong","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wetz, C., Genseke, P., Apostolova, I., Furth, C., Ghazzawi, S., Rogasch, J.M.M., Schatka, I., Kreissl, M.C., Hofheinz, F., and Grosser, O.S. (2019). The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [177Lu]-DOTATATE. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0216781"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2124750","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.2967\/jnumed.120.258772","article-title":"Surgical feasibility, determinants, and overall efficacy of neoadjuvant 177Lu-DOTATATE PRRT for locally advanced unresectable gastroenteropancreatic neuroendocrine tumors","volume":"62","author":"Parghane","year":"2021","journal-title":"J. Nucl. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3317\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:44:08Z","timestamp":1760139848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/14\/3317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":29,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["cancers14143317"],"URL":"https:\/\/doi.org\/10.3390\/cancers14143317","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,7]]}}}